Cel Sci (CVM) EBIT Growth (3y) (2013 - 2026)
Cel Sci (CVM) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | -18.82% |
| 10 | Cel Sci | 2.15 Mn | -4.39 Mn | - | 12.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.31% |
| Dec 31, 2025 | 11.14% |
| Sep 30, 2025 | 12.31% |
| Jun 30, 2025 | 14.30% |
| Mar 31, 2025 | 12.52% |
| Dec 31, 2024 | 7.97% |
| Sep 30, 2024 | 10.28% |
| Jun 30, 2024 | 13.92% |
| Mar 31, 2024 | 6.05% |
| Dec 31, 2023 | 9.43% |
| Sep 30, 2023 | 4.02% |
| Jun 30, 2023 | -5.51% |
| Mar 31, 2023 | -6.77% |
| Dec 31, 2022 | -3.72% |
| Sep 30, 2022 | -16.60% |
| Jun 30, 2022 | -18.73% |
| Mar 31, 2022 | -30.41% |
| Dec 31, 2021 | -20.66% |
| Sep 30, 2021 | -33.87% |
| Jun 30, 2021 | -36.76% |